Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2006-10-03
2006-10-03
Helms, Larry R. (Department: 1643)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C530S388260, C530S388800, C424S131100, C424S146100, C424S155100, C435S070210
Reexamination Certificate
active
07115715
ABSTRACT:
Herein disclosed is a novel oncogene named MN or alternatively MN/CA IX. Abnormal expression of the MN gene is shown to signify oncogenesis, and diagnostic/prognostic methods for pre-neoplastic
eoplastic disease to detect or detect and quantitate such abnormal MN gene expression. Also disclosed are methods to treat pre-neoplastic
eoplastic disease involving the MN gene and protein, e.g., methods comprising the use of MN-specific antibodies, anti-idiotype antibodies thereto, and anti-anti-idiotype antibodies, and the use of MN antisense nucleic acids. Further disclosed are methods to identify and block MN binding site(s) and identify MN protein partners(s).
REFERENCES:
patent: 5270202 (1993-12-01), Raychaudhuri
patent: 5387676 (1995-02-01), Zavada et al.
patent: 5585479 (1996-12-01), Hoke et al.
patent: 6235280 (2001-05-01), Chatterjee et al.
patent: 6632431 (2003-10-01), Wu
patent: 8808854 (1988-11-01), None
patent: 9318152 (1993-09-01), None
patent: 9534650 (1995-12-01), None
William E. Paul, ed., Fundamental Immunology, 3rd ed. p. 242, 1993.
Raychaudhuri et al. The Journal of Immunology, 13(5):1743-1749, 1986.
Uemura et al. British journal of Cancer, 81(4):741-746, 1999.
Anton et al., “Localized renal-cell carcinoma: detection of abnormal cells in peritumoral tissue. A cytophotometry and immunocytochemistry study,”World J. Urol., 13(3): 149-152 (1995).
Bander et al., “Renal cancer imaging with monoclonal antibody G250,”J. Urol., 155 (5 Suppl.): 583A (Abstract 1088) (1996).
Brewer et al., “A Study of Biomarkers in Cervical Carcinoma and Clinical Correlation of the Novel Biomarker MN,”Gynecologic Oncology, 63: 337-344 (1996).
Costa et al., “MN Protein Immunolocalization in Uterine Cervix Carcinoma With Glandular Differentiation—A Clinicopathologic Study of a New Cancer-specific Biomarker,”International Journal of Surgical Pathology, 3(2): 73-82 (1995).
Costa, M., “MN and Ki67 (MIB-1) in Uterine Cervix Carcinoma: Novel Biomarkers With Divergent Utility,”Human Pathology, 27(3): 217-219 (Mar. 1996).
Cote, “Protein Antigen Helps Identify Early Cervical Abnormalities,”Women's Health Weekly: News Section, p. 7 (Mar. 30, 1998).
Divgi et al., “Scintigraphy of Renal Cell Carcinoma with I-131 Labelled Monoclonal Antibody (MAB) G250,”European Journal of Nuclear Medicine, 19(8): 578 (Abstract 121-3) (Aug. 23, 1992).
Divgi et al., “Radioimmunotherapy (RIT) with I-131 Monoclonal Antibody (Mab) G250 in Metastatic Renal Cancer,”Proceedings of the 41stAnnual Meeting, 35(5): 101P (Abstract #401) (May 1994).
Divgi et al., “Radioimmunotherapy with I-131-G250 in Metastatic Renal Cell Cancer (RCC),”J. Nucl. Med., 36 (5 Suppl.): 913P (Abstract 956; May 1995).
Frohman et al., “Rapid production of full-length cDNAs from rare transcripts: Amplification using a single gene-specific oligonucleotide primer,”PNAS(USA), 85: 8998-9002 (Dec. 1988).
Frosch et al., “Cloning and characterisation of an immunodominant major surface antigen ofEchinococcus multilocularis,” Molecular and Biochemical Parasitology, 48: 121-130 (1991).
Ivanov et al., “Down-regulation of transmembrane carbonic anhydrases in renal cell carcinoma cell lines by wild-type von Hippel-Lindau transgenes,”PNAS(USA) 95: 12596-12601 (Oct. 1998).
Karttunen et al., “Colorectal Tumors Show Abnormal Expression of MN/CA IX,”Pathology Research and Practice 193/5-6: 392 Abstract No. P198 (Abstract from European Congress on Pathology at Maastricht; Aug. 31-Sep. 4, 1997).
Kranenborg et al., “Development and Characterization of Anti-Renal Cell Carcinoma X Antichelate Bispecific Monoclonal Antibodies for Two-Phase Targeting of Renal Cell Carcinoma,”Cancer Res., 55 (23 Suppl.) 5864s-5867s (1995).
Kurth et al., “Characterization of Human Renal Cell Carcinoma Tumor Lines by Means of Monoclonal Antibodies,”Prostate, 6(4): 451 (Abstract) (1985).
Liao et al., “Identification of the MN Antigen as a Diagnostic Biomarker of Cervical Intraepithelial Squamous and Glandular Neoplasia and Cervical Carcinomas,”American Journal of Pathology, 145(3): 598-609 (Sep. 1994).
Liao and Stanbridge, “Expression of the MN Antigen in Cervical Papanicolaou Smears Is an Early Diagnostic Biomarker of Cervical Dysplasia,”Cancer Epidemiology, Biomarkers&Prevention, 5: 549-557 (Jul. 1996).
Liao et al., “Identification of the MN/CA9 Protein As a Reliable Diagnostic Biomarker of Clear Cell Carcinoma of the Kidney,”Cancer Research, 57: 2827-2831 (Jul. 15, 1997).
Luiten et al., “Target-Specific Activation of Mast Cells by Immunoglobulin E Reactive with a Renal Cell Carcinoma-Associated Antigen,”Laboratory Investigation, 74(2): 467-475 (1996).
Luiten et al., “Generation of chimeric bispecific G250/anti-CD3 monoclonal antibody, a tool to combat renal cell carcinoma,”British Journal of Cancer, 74(5): 735-744 (1996).
Luner et al., “Monoclonal Antibodies to Kidney and Tumor-associated Surface Antigens of Human Renal Cell Carcinoma,”Cancer Res., 46(11): 5816-5820 (1986).
McKiernan et al., “Expression of the Tumor-associated GeneMN: A Potential Biomarker for Human Renal Cell Carcinoma,”Cancer Research, 57: 2362-2365 (Jun. 15, 1997).
Moon et al., “A Highly Restricted Antigen for Renal Cell Carcinoma Defined by a Monoclonal Antibody,”Hybridoma, 4(2): 163-172 (1985).
Nakagawa et al., “MN as a Potential Target in Renal Cell Carcinoma,”J. Urology, 159 (5 Suppl.): 187, Abstract 720 (May 1998).
Oosterwijk and Debruyne, “Radiolabeled monoclonal antibody G250 in renal-cell carcinoma,”World Journal of Urology, 13: 186-190 (1995).
Oosterwijk et al., “The Expression of Renal Antigens in Renal Cell Carcinoma,”World Journal of Urology, 2(2): 156-158 (1984).
Oosterwijk et al., “Monoclonal Antibodies that Discriminate Between Renal Cell Carcinomas (RCC) and Other Malignancies,”Prostate, 6(4): 451-452 (Abstract) (1985).
Oosterwijk et al., “Immunohistochemical Analysis of Monoclonal Antibodies to Renal Antigens—Application in the Diagnosis of Renal Cell Carcinoma,”American Journal of Pathology, 123(2): 301-309 (May 1986).
Oosterwijk et al., “Monoclonal Antibody G250 Recognizes a Determinant Present in Renal-Cell Carcinoma and Absent from Normal Kidney,”Int. J. Cancer, 38: 489-494 (1986).
Oosterwijk et al., “Relationship between DNA Ploidy, Antigen Expression and Survival in Renal Cell Carcinoma,”Int. J. Cancer, 42: 703-708 (1988).
Oosterwijk et al., “Expression of Intermediate-sized Filaments in Developing and Adult Human Kidney and Renal Cell Carcinoma,”The Journal of Histochemistry and Cytochemistry, 38(3): 385-392 (1990).
Oosterwijk et al., “Antibody Localization in Human Renal Cell Carcinoma: A Phase I Study of Monoclonal Antibody G250,”Journal of Clinical Oncology, 11(4): 738-750 (Apr. 1993).
Oosterwijk et al., “The Use of Monoclonal Antibody G250 in the Therapy of Renal-Cell Carcinoma,”Seminars in Oncology, 22(1): 34-41 (Feb. 1995).
Oosterwijk et al., “Molecular characterization of the Renal Cell Carcinoma-associated antigen G250,”Proceedings of the American Association for Cancer Research, 37: 461 (Abstract #3147) (Mar. 1996).
Oosterwijk et al., “Molecular Characterization of the Renal Cell Carcinoma-Associated Antigen G250,”J. Urol., 155: 925 (May 1996).
Opavsky et al., “Regulation of MN Expression,”Cell Biology International, 18(5): Abstract No. Mo-58 (1994).
Opavsky et al., “Human MN/CA9 Gene a Novel Member of the Carbonic Anhydrase Family: Structure and Exon to Protein Domain Relationships,”Genomics, 33: 480-487 (1996).
Pastorek et al., “The Structure and Expression of MN Gene, Coding for a Tumor-Associated Protein p54/58N,”J. Cancer Res., Clin. Oncol, 119 (Suppl.
Pastorek Jaromir
Pastorekova Silvia
Zavada Jan
Blanchard David J.
Harland Joan C.
Helms Larry R.
Institute of Virology Slovak Academy of Sciences
Lauder Leona L.
LandOfFree
Anti-idiotype antibodies to MN proteins and MN polypeptides does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Anti-idiotype antibodies to MN proteins and MN polypeptides, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anti-idiotype antibodies to MN proteins and MN polypeptides will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3681751